Glenmark Pharmaceuticals Limited (GLENMARK.NS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Glenn Mario Saldanha | Chairman, MD & CEO | 161.85M | -- | 1970 |
| Mr. V. S. Mani | Global CFO & Executive Director | 102.47M | -- | 1965 |
| Ms. Cherylann Maria Pinto | Executive Director of Corporate Services & Executive Director | 45.86M | -- | 1967 |
| Mr. Harish Vinayak Kuber | Company Secretary & Compliance Officer | -- | -- | -- |
| Mr. Alind Sharma | President and Chief Human Resources Officer | -- | -- | 1971 |
| Mr. Sanjeev Krishan | President and Business Head of North America | -- | -- | -- |
| Mr. Ulhas R. Dhuppad | President & Head of Global Pharmaceutical Development | -- | -- | 1967 |
| Mr. Indrajit Bose | President & Chief Quality Officer | -- | -- | -- |
| Mr. Brijlal Motwani | President & Global Head of Formulation Operations | -- | -- | -- |
| Mr. Alok Malik | President & Business Head of India Formulations | -- | -- | -- |
Glenmark Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 15,556
Description
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.
Corporate Governance
Recent Events
- Sep 18, 2023Ex-Dividend Date